Business
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agent
About this update from Bioatla, Inc.
[{"type":"image","alt":"BioAtla, Inc.","displaySize":"","headline":null,"caption":"BioAtla, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":164,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z8G3hxIezptosVzATIpKBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348","width":164,"height":75}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agents","length":309,"tagName":"p"}]},{"val":[{"type":"text","content":"Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fast Track Designation for additional discussions with the U.S. Food & Drug Administration (FDA) for guidance on a proposed Phase 3 study","length":337,"tagName":"p"}]},{"val":[{"type":"text","content":"Current cash balance projected to fund operations beyond key clinical readouts in 1H 2026","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Management to host conference call and webcast today at 4:30 PM Eastern Time","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1008,"olType":false},{"type":"text","content":"SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2025 and provided highlights on its clinical programs.","length":373,"tagName":"p"},{"type":"text","content":...